Maravai’s revenue guidance for the full year 2025 is based on expectations for its existing base business and does not include revenue, if any, from high-volume CleanCap orders for commercial phase vaccine programs, or potential new acquisitions, if any, or items that have not yet been identified or quantified.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- MRVI Upcoming Earnings Report: What to Expect?
- MRVI Lawsuit Alert! Class Action Lawsuit Against Maravai Lifesciences Holdings
- Maravai Lifesciences price target lowered to $5 from $7 at Morgan Stanley
- Maravai LifeSciences Earnings Call: Growth Amid Challenges
- Biotech Alert: Searches spiking for these stocks today